E02_08 Asthma Flashcards
2017, 2018_Bronchial Asthma
Which one of the following statements regarding the use of corticosteroids is false?
A. Corticosteroids may potentiate the use of Beta-2 Adrenergic Agonist
B. Corticosteroids may decrease hospital admission rates
C. Aminophylline does not potentiate the benefits of corticosteroids
D. Corticosteroids increase the release of arachidonic acid
D. Corticosteroids increase the release of arachidonic acid
2017, 2018_Bronchial Asthma
Mr. Smith has about 2 asthmatic episodes per month. His PFTs show an FEV1 of 85% of predicted. You prescribe:
A. Allergen avoidance alone
B. Allergen avoidance and “as needed” use of albuterol
C. Albuterol inhaler daily with an inhaled corticosteroid
D. A 10-day course of oral steroids followed by daily albuterol
B. Allergen avoidance and “as needed” use of albuterol
2017, 2018_Bronchial Asthma
Indicate which of the following statements about mast cell stabilizers is correct:
A. Effective after a single dose in decreasing bronchial inflammation of chronic asthma
B. Highly effective rescue medicine when used during acute bronchospasm
C. NHLBI (National Heart, Lung and Blood Institute) National Asthma Education Program consensus guideline recommends mast cell stabilizers as the preferred treatment for persistent asthma
D. Effective option in prophylaxis of mild to moderate persistent asthma and exercise- induced asthma
E. Use is limited due to frequent adverse effects, 1ith >10% of patients reporting dysphonia (difficulty or pain in speaking), thrush and headache
D. Effective option in prophylaxis of mild to moderate persistent asthma and exercise- induced asthma
2017, 2018_Bronchial Asthma
All of the following statements about the role of theophylline in asthma management is correct except:
A. Narrow therapeutic window needing serum drug level monitoring and has multiple drug interactions
B. Side effects like insomnia, agitation, nausea, loose stools and tachycardia limit tolerability
C. Results in bronchodilation by enhancing the activity of endogenous Beta Adrenergic Agonist D. Results in anti-inflammatory activity by antagonizing the adenosine mediated proinflammatory activity
E. Is used as a rescue medicine for patients taking MAOIs who cannot receive beta adrenergic agonists
E. Is used as a rescue medicine for patients taking MAOIs who cannot receive beta adrenergic agonists
2017, 2018_Bronchial Asthma
All of the following medication categories are asthma controller medications, which affect the underlying causes of the disease, except:
A. Inhaled corticosteroids
B. Inhaled muscarinic receptor antagonist
C. Leukotriene receptor agonist
D. Mast cell stabilizer
B. Inhaled muscarinic receptor antagonist
2017, 2018_Bronchial Asthma
All of the following statements about the role of inhaled cortricosteroids in the management of asthma are correct except:
A. Due to the frequent side effects of inhaled corticosteroids (thrush, Cushingoid changes, growth retardation in children, acute adrenal insuffeciency, etc) their role is limited to prophylaxis of severe persistent asthma
B. Inhaled corticosteroids are not effective in the relief of acute bronchoconstriction
C. Long term corticosteroid use results in the up regulation of beta adrenergic receptors enhancing responsiveness to inhaled beta adrenergic agonists
D. Corticosteroids inhibit the release of leukotrienes and decrease IgE synthesis and decrease airway inflmmation
E. Inhaled corticosteroids can be combined with long acting beta adrengergic agonists to suppress airway inflammation and hyper-activity in moderate to severe persistent asthma
A. Due to the frequent side effects of inhaled corticosteroids (thrush, Cushingoid changes, growth retardation in children, acute adrenal insuffeciency, etc) their role is limited to prophylaxis of severe persistent asthma
2017, 2018_Bronchial Asthma
Simple instrument to roughly determine lung function is a:
A. Barometer
B. Manometer
C. Peak flow meter
D. Sphygmomanometer
C. Peak flow meter
2017, 2018_Bronchial Asthma
This bronchodilator is commonly used when doing the reversibility test: A. Salbutamol B. Atropine C. Theophylline D. Adrenaline
A. Salbutamol
2017, 2018_Bronchial Asthma
The following are helpful in determining severity of asthma except:
A. Ability to speak in sentences
B. Use of accessory muscles
C. Peak expiratory flow rate
D. Pedal edema
D. Pedal edema
2017, 2018_Bronchial Asthma
The mechanism of action of beta 2 adrenergic agonist in bronchial asthma includes the following except:
A. Relaxation of smooth muscle airway
B. Inhibition of plasma exudation and airway edema
C. Increased mucociliary clearance
D. Increasing the release of mast cell mediators
D. Increasing the release of mast cell mediators
2017, 2018_Bronchial Asthma
Which is a wrong statement by a patient about using an inhaler, who is on treatment for asthma?
A. I should inhale before using my inhaler
B. I should place my lips firmly around the mouthpiece.
C. I should hold my breath for about 8-10 seconds after using the inhaler
D. I should wait 1-2 minutes between puffs
A. I should inhale before using my inhaler
2017, 2018_Bronchial Asthma
Which of the following drugs is a leukotriene modifying drug indicated as a controller in the management of bronchial asthma?
A. Triamcinolone
B. Budesonide
C. Monteleukast
D. Flunisolide
C. Monteleukast
2018_Bronchial Asthma
Exerts activity by inhibiting 5-lipooxygenase to prevent synthesis of leukotrienes from arachidonic acid
A. Zafirlukast B. Montelukast C. Zileuton D. Cromolyn E. Methylxanthines
C. Zileuton
D and E are out since they don’t have anything to do with leukotrienes. Zafirlukast and montelukast are both leukotriene receptor antagonists (of D4/E4 and D4 receptors respectively), while zileuton directly inhibits 5-lipooxygenase, preventing formation of LTB4, LTC4, LTD4, and L TE4.
